title: Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells.
abstract: BACKGROUND
  The major cause of death from cancer is metastases that are resistant to conventional therapies. The resistance of metastatic tumor cells to chemotherapy can be caused by their intrinsic properties, such as increased expression of the mdr genes.
  
  
  OBJECTIVE
  The purpose of our present study was to determine some of the mechanisms by which the organ microenvironment influences the response of tumor cells to chemotherapy.
  
  
  METHODS
  Murine CT-26 colon cancer cells growing in continuous culture (parental cells) were harvested and injected subcutaneously into the lateral flank (to produce subcutaneous tumors) or the lateral tail vein (to produce experimental lung metastases) of 10 8-week-old syngeneic male BALB/c mice. Seven days after tumor-cell injection, the mice were given intravenous injections of either doxorubicin (10 mg/kg) or 0.9% NaCl (controls). This in vivo injection was repeated 7 days later. Mice with subcutaneous tumors and lung metastases were killed by cervical dislocation on day 21, and tumor samples from control mice were harvested and adapted to culture. The sensitivity of the cultured cells to doxorubicin and fluorouracil (5-FU) was determined at multiple time points. Levels of mdr-1 DNA were measured by slot-blot and Southern-blot analyses. mdr mRNA expression levels were measured by Northern-blot analysis using mdr-1- and mdr-3-specific hybridization probes, and P-glycoprotein level was determined by fluorescence-activated cell sorting using different monoclonal antibodies.
  
  
  RESULTS
  Treatment with doxorubicin produced 80% growth inhibition of CT-26 subcutaneous tumors but had little effect on the number (and size) of experimental lung metastases. Collectively, the results suggest that the multidrug-resistant phenotype developed in CT-26 cells growing in the lung environment. Cultures established from lung metastases were initially resistant to doxorubicin (but not to 5-FU) and showed elevated expression of mdr-1 mRNA transcripts and P-glycoprotein. This resistance could be overcome by verapamil and disappeared after 21 days in culture. No mdr gene amplification was detected. The expression level of mdr-specific mRNA (predominance of mdr-1) and P-glycoprotein was directly associated with resistance to doxorubicin.
  
  
  CONCLUSIONS
  Results of this study have demonstrated that the in vivo sensitivity of murine CT-26 colon carcinoma cells to doxorubicin depends on the organ environment. The organ environment can influence the P-glycoprotein-mediated multidrug-resistant phenotype in tumor cells, and the increased expression of P-glycoprotein is transient; once removed from the environment (lung), the cell's resistance reverts to that of the sensitive parent cells.
authors.affiliation: Department of Cell Biology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
authors.forename: Z
authors.initials: Z
authors.lastname: Dong
authors.forename: R
authors.initials: R
authors.lastname: Radinsky
authors.forename: D
authors.initials: D
authors.lastname: Fan
authors.forename: R
authors.initials: R
authors.lastname: Tsan
authors.forename: C D
authors.initials: CD
authors.lastname: Bucana
authors.forename: C
authors.initials: C
authors.lastname: Wilmanns
authors.forename: I J
authors.initials: IJ
authors.lastname: Fidler
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000818:Animals; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics; D002352:Carrier Proteins / Q000235:genetics*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D004317:Doxorubicin / Q000008:administration & dosage; D004351:Drug Resistance; D015870:Gene Expression; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008562:Membrane Glycoproteins / Q000235:genetics*; D051379:Mice; D008807:Mice, Inbred BALB C; D009362:Neoplasm Metastasis; D012333:RNA, Messenger / Q000235:genetics; D012334:RNA, Neoplasm / Q000235:genetics; D012878:Skin Neoplasms / Q000188:drug therapy; D014700:Verapamil / Q000008:administration & dosage
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D004317:Doxorubicin; D014700:Verapamil